Microchip Technology Incorporated · MCHP · FY2025 Q4 · Calendar Q2 2025
Microchip sees inventory progress, AI momentum and margin risks
The supplied analysis supports a conditional recovery case: inventory reduction, stronger bookings, AI and network growth, and aerospace and defense demand could improve the trajectory, but margin recovery and cash flow remain unproven.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about MCHP FY2025 Q4
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The latest analysis shows further inventory progress, increased emphasis on AI and network connectivity, and aerospace and defense as growth contributors. It also flags a redesigned China-for-China strategy and continued exposure to underutilization, tariffs and cash-flow volatility.
Guidance delta
Maintained; management positioned the June quarter as the revenue bottom and highlighted a 1.07 book-to-bill ratio.
Key takeaways
- Inventory days have declined, with further reduction targeted for FY2026.
- Management highlighted AI and network connectivity, aerospace and defense, and new product launches as growth drivers.
- Margin recovery depends on destocking, fab utilization and improved bookings.
- The dividend is unchanged despite near-term free-cash-flow constraints.
Management priorities
- Reduce inventory toward the FY2026 target.
- Ramp fab capacity as inventory declines and demand improves.
- Expand AI products, including the MPLAB AI coding assistant.
- Advance Switchtec, PIC64 and other new product introductions.
- Rework the China-for-China strategy for new fab-diffusion rules.
Follow MCHP with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 4, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| BMO Capital | Outperform | Outperform | Maintain | Aug 21, 2026 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Aug 17, 2026 |
| UBS | Buy | Buy | Maintain | Aug 7, 2026 |
| Truist Securities | Hold | Hold | Maintain | Aug 7, 2026 |
| Rosenblatt | Buy | Buy | Maintain | Aug 7, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 7, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jul 20, 2026 |
| TD Cowen | Hold | Hold | Maintain | Jul 13, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | May 11, 2026 |
| Susquehanna | Positive | Positive | Maintain | May 8, 2026 |
| Needham | Buy | Buy | Maintain | May 8, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | May 8, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | May 8, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Feb 6, 2026 |
| B of A Securities | Neutral | Neutral | Maintain | Jan 21, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jan 15, 2026 |
| B. Riley Securities | Buy | Buy | Maintain | Jan 12, 2026 |
| Stifel | Buy | Buy | Maintain | Jan 6, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jan 6, 2026 |
| Raymond James | Strong Buy | Strong Buy | Maintain | Aug 8, 2025 |
| Keybanc | Overweight | Overweight | Maintain | Jul 8, 2025 |
| Goldman Sachs | Neutral | Neutral | Maintain | Jan 10, 2025 |
| Jefferies | Buy | Buy | Maintain | Nov 6, 2024 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Jan 18, 2024 |
| Credit Suisse | Neutral | Neutral | Maintain | Feb 3, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Aug 3, 2022 |
| Longbow Research | Buy | Neutral | Upgrade | Mar 23, 2021 |
| B. Riley FBR | Buy | Buy | Maintain | Feb 5, 2021 |
| Vertical Research | Neutral | Buy | Downgrade | Feb 3, 2021 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Jun 3, 2020 |
| CFRA | Hold | Hold | Maintain | May 8, 2020 |
| B. Riley | Buy | Buy | Maintain | Nov 6, 2019 |
| Bank of America | Neutral | Buy | Downgrade | Sep 17, 2018 |
| Nomura | Buy | Buy | Maintain | Aug 10, 2018 |
| PiperJaffray | Overweight | Overweight | Maintain | Jul 27, 2018 |
| Argus | Buy | Buy | Maintain | Oct 6, 2017 |
| Summit Redstone Partners | Buy | Hold | Upgrade | Apr 4, 2017 |
| Summit Insights Group | Buy | Hold | Upgrade | Apr 4, 2017 |
| CLSA | Buy | Buy | Maintain | May 17, 2016 |
| Stifel Nicolaus | Buy | Buy | Maintain | Aug 4, 2015 |
| Drexel Hamilton | Hold | Buy | Downgrade | Oct 10, 2014 |
| Stephens & Co. | Equal Weight | Overweight | Downgrade | Nov 18, 2013 |
| ISI Group | Strong Buy | Buy | Upgrade | Mar 4, 2013 |
| Miller Tabak | Neutral | Neutral | Maintain | Oct 16, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $81.32. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Truist Financial | Analyst unavailable | $90 | $84.81 | +10.7% | Aug 7, 2026 |
| UBS | Analyst unavailable | $120 | $74.36 | +47.6% | Aug 7, 2026 |
| Jefferies | Analyst unavailable | $100 | $74.36 | +23.0% | Aug 7, 2026 |
| Wells Fargo | Joe Quatrochi | $88 | $80.96 | +8.2% | Jul 20, 2026 |
| Barclays | Tom O'Malley | $105 | $99.09 | +29.1% | May 11, 2026 |
| UBS | Analyst unavailable | $130 | $97.97 | +59.9% | May 8, 2026 |
| Needham | Quinn Bolton | $120 | $98.64 | +47.6% | May 8, 2026 |
| Susquehanna | Analyst unavailable | $120 | $99.59 | +47.6% | May 8, 2026 |
| Truist Financial | William Stein | $105 | $98.7 | +29.1% | May 8, 2026 |
| Morgan Stanley | Analyst unavailable | $94 | $99.6 | +15.6% | May 8, 2026 |
| Raymond James | Melissa Fairbanks | $125 | $99.58 | +53.7% | May 8, 2026 |
| Evercore ISI | Mark Lipacis | $117 | $101.14 | +43.9% | May 8, 2026 |
| Mizuho Securities | Analyst unavailable | $112 | $101.58 | +37.7% | May 8, 2026 |
| KeyBanc | Analyst unavailable | $135 | $101.58 | +66.0% | May 8, 2026 |
| Jefferies | Analyst unavailable | $120 | $101.58 | +47.6% | May 8, 2026 |
| Barclays | Tom O'Malley | $80 | $80.75 | -1.6% | Feb 12, 2026 |
| Truist Financial | Analyst unavailable | $69 | $76.86 | -15.2% | Feb 10, 2026 |
| Stifel Nicolaus | Tore Svanberg | $90 | $75.58 | +10.7% | Feb 6, 2026 |
| Cantor Fitzgerald | Matthew Prisco | $100 | $75.54 | +23.0% | Feb 6, 2026 |
| Truist Financial | Analyst unavailable | $68 | $75.28 | -16.4% | Feb 6, 2026 |
| KeyBanc | John Vinh | $85 | $75.96 | +4.5% | Feb 6, 2026 |
| Evercore ISI | Mark Lipacis | $93 | $74.21 | +14.4% | Feb 6, 2026 |
| Mizuho Securities | Analyst unavailable | $90 | $78.04 | +10.7% | Feb 6, 2026 |
| Needham | Analyst unavailable | $84 | $78.04 | +3.3% | Feb 6, 2026 |
| Industrial Alliance Securities | Analyst unavailable | $100 | $77.12 | +23.0% | Feb 2, 2026 |
| UBS | Analyst unavailable | $95 | $74.7 | +16.8% | Jan 26, 2026 |
| Susquehanna | Analyst unavailable | $90 | $74.91 | +10.7% | Jan 22, 2026 |
| BNP Paribas | David O'Connor | $90 | $76.2 | +10.7% | Jan 22, 2026 |
| UBS | Analyst unavailable | $78 | $75.51 | -4.1% | Jan 21, 2026 |
| Piper Sandler | Analyst unavailable | $85 | $74.68 | +4.5% | Jan 15, 2026 |
| Mizuho Securities | Analyst unavailable | $83 | $74.06 | +2.1% | Jan 9, 2026 |
| Morgan Stanley | Analyst unavailable | $69 | $74.87 | -15.2% | Jan 7, 2026 |
| Stifel Nicolaus | Tore Svanberg | $80 | $67.06 | -1.6% | Jan 6, 2026 |
| Wolfe Research | Analyst unavailable | $85 | $67.06 | +4.5% | Jan 6, 2026 |
| Mizuho Securities | Vijay Rakesh | $80 | $67.2 | -1.6% | Dec 16, 2025 |
| Cantor Fitzgerald | CJ Muse | $85 | $67.2 | +4.5% | Dec 16, 2025 |
| Needham | Analyst unavailable | $75 | $63.99 | -7.8% | Dec 4, 2025 |
| Truist Financial | William Stein | $60 | $56.28 | -26.2% | Nov 9, 2025 |
| Cantor Fitzgerald | Analyst unavailable | $65 | $55.34 | -20.1% | Nov 7, 2025 |
| Morgan Stanley | Joseph Moore | $68 | $60.25 | -16.4% | Nov 4, 2025 |
| Needham | Quinn Bolton | $77 | $62.97 | -5.3% | Aug 8, 2025 |
| Raymond James | Melissa Fairbanks | $75 | $61.87 | -7.8% | Aug 8, 2025 |
| Cantor Fitzgerald | Matthew Prisco | $70 | $68.02 | -13.9% | Jun 18, 2025 |
| Evercore ISI | Mark Lipacis | $83 | $67.93 | +2.1% | Jun 12, 2025 |
| Truist Financial | Analyst unavailable | $43 | $39.43 | -47.1% | Apr 21, 2025 |
| Mizuho Securities | Analyst unavailable | $68 | $58.14 | -16.4% | Mar 4, 2025 |
| Morgan Stanley | Joseph Moore | $58 | $52.6 | -28.7% | Feb 4, 2025 |
| KeyBanc | Weston Twigg | $90 | $70.31 | +10.7% | Dec 3, 2024 |
| Truist Financial | William Stein | $71 | $74.4 | -12.7% | Nov 6, 2024 |
| Needham | Rajvindra Gill | $85 | $74.4 | +4.5% | Nov 6, 2024 |
| Evercore ISI | Mark Lipacis | $95 | $74.4 | +16.8% | Nov 6, 2024 |
| KeyBanc | Weston Twigg | $95 | $74.4 | +16.8% | Nov 6, 2024 |
| Raymond James | Melissa Fairbanks | $95 | $74.4 | +16.8% | Nov 6, 2024 |
| Mizuho Securities | Vijay Rakesh | $95 | $76.58 | +16.8% | Oct 18, 2024 |
| Truist Financial | William Stein | $80 | $77.01 | -1.6% | Sep 23, 2024 |
| Citigroup | Christopher Danely | $92 | $80.28 | +13.1% | Aug 21, 2024 |
| Rosenblatt Securities | Hans Mosesmann | $90 | $74.67 | +10.7% | Aug 5, 2024 |
| Mizuho Securities | Vijay Rakesh | $115 | $98.14 | +41.4% | May 23, 2024 |
| Piper Sandler | Harsh Kumar | $90 | $93.02 | +10.7% | May 7, 2024 |
| Needham | Rajvindra Gill | $100 | $93.76 | +23.0% | May 7, 2024 |
| Mizuho Securities | Vijay Rakesh | $85 | $93.76 | +4.5% | May 7, 2024 |
| Evercore ISI | Mark Lipacis | $106 | $85.7 | +30.3% | Apr 15, 2024 |
| Wolfe Research | Chris Caso | $105 | $83.34 | +29.1% | Jan 17, 2024 |
| Credit Suisse | Analyst unavailable | $85 | $76.94 | +4.5% | Nov 16, 2022 |
| Piper Sandler | Harsh Kumar | $80 | $59.46 | -1.6% | Nov 3, 2022 |
| Goldman Sachs | Toshiya Hari | $61 | $65.31 | -25.0% | Jul 27, 2022 |
| Stifel Nicolaus | Tore Svanberg | $75 | $59.45 | -7.8% | Jun 28, 2022 |
| BMO Capital | Ambrish Srivastava | $85 | $68.25 | +4.5% | May 11, 2022 |
| Wells Fargo | Gary Mobley | $80 | $72.92 | -1.6% | Feb 4, 2022 |
| B.Riley Financial | Craig Ellis | $105 | $72.92 | +29.1% | Feb 4, 2022 |
| Needham | Rajvindra Gill | $105 | $72.92 | +29.1% | Feb 4, 2022 |
| Cowen & Co. | Matt Ramsay | $78 | $72.92 | -4.1% | Feb 4, 2022 |
| BMO Capital | Ambrish Srivastava | $95 | $72.92 | +16.8% | Feb 4, 2022 |
| Citigroup | Christopher Danely | $78 | $72.92 | -4.1% | Feb 4, 2022 |
| Raymond James | Chris Caso | $110 | $85.22 | +35.3% | Nov 5, 2021 |
| Credit Suisse | John Pitzer | $120 | $85.22 | +47.6% | Nov 5, 2021 |
| Piper Sandler | Harsh Kumar | $100 | $85.22 | +23.0% | Nov 5, 2021 |
| Morgan Stanley | Joseph Moore | $100 | $85.22 | +23.0% | Nov 5, 2021 |
| KeyBanc | John Vinh | $92.5 | $72.38 | +13.7% | Jul 6, 2021 |
Track every rating change on MCHP the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationMicrochip Technology Incorporated creates, produces, and sells intelligent, interconnected, and secure embedded control solutions to customers throughout the Americas, Europe, and Asia. The company's core offerings include a range of microcontrollers, such as general-purpose 8-bit, 16-bit, and 32-bit models, as well as 32-bit embedded microprocessors. These specialized microcontrollers are designed for numerous applications across industries like automotive, industrial, computing, communications, lighting, power supplies, motor control, human-machine interfaces, security, and various wired and wireless connectivity needs. Beyond its processors, Microchip provides development tools that enable system designers to program its microcontroller and microprocessor units for specific tasks. Its product lineup also features Field-Programmable Gate Arrays (FPGAs) and a broad selection of analog, interface, mixed-signal, and timing components.…
Historical context
All MCHP earningsTechnology peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| ACN Accenture plc | FY2026 Q4 · Calendar Q4 2026 | +3.5% | +15.8% | Accenture: AI demand supports strong Q4, while pricing and geopolitics remain risks |
| JBL Jabil Inc. | FY2026 Q4 · Calendar Q3 2026 | +8.1% | -10.0% | Jabil enters FY2027 with AI-led growth and capacity risks |
| MU Micron Technology, Inc. | FY2026 Q4 · Calendar Q3 2026 | +5.4% | +0.0% | Micron: Strong AI Memory Demand, Higher Capex, and HBM4E Ahead |
| SNX TD Synnex Corp | FY2026 Q3 · Calendar Q3 2026 | +20.9% | -9.9% | TD SYNNEX: AI-led growth accelerates, but mix and cash flow matter |
| ADBE Adobe Inc. | FY2026 Q3 · Calendar Q3 2026 | +0.8% | +1.4% | Adobe raises FY26 outlook as AI strategy broadens |
| ORCL Oracle Corporation | FY2027 Q1 · Calendar Q3 2026 | +10.3% | -1.7% | Oracle raises FY27 outlook as AI demand accelerates cloud growth |
Latest beats and misses
Who reports nextBeat on EPS
- ACNFY2026 Q4 · October 1, 2026+3.5% EPS+15.8% move
- MKCFY2026 Q3 · October 1, 2026+13.9% EPS-4.9% move
- NKEFY2027 Q1 · October 1, 2026+10.0% EPS-0.7% move
- CAGFY2027 Q1 · September 30, 2026+44.4% EPS-4.9% move
- FDSFY2026 Q4 · September 30, 2026+3.9% EPS+3.8% move
- JBLFY2026 Q4 · September 30, 2026+8.1% EPS-10.0% move
Get the MCHP recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-04-26T17:36:45.894372+00:00
- Polygon adjusted daily market bars · 2026-10-04T09:40:42.822576+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-04T09:40:42.819773+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-04. For educational purposes only; not investment advice.